The Skull as Therapeutic Infrastructure: How CraniUS and Chronic Convection Delivery Bypass the Blood-Brain Barrier
Dr. Dereck Mush, MD, MBA
CraniUS Therapeutics
Patient-specific cranial implants that form the foundation of a skull-embedded, direct-to-brain drug delivery platform.
What they do
CraniUS builds the NeuroPASS platform: patient-specific PEEK cranioplasty plates cleared by the FDA (NeuroPASS 1 in July 2026 under K261058, NeuroPASS 2 in September 2026 under K262874, which adds openings for an implantable intracranial pressure sensor). An issued US patent protects NeuroPASS 3, an investigational fully implantable convection drug delivery pump designed to bypass the blood-brain barrier, with a first-in-human study in recurrent glioblastoma targeted for 2027. The company has NIH Blueprint MedTech funding of up to $4M and closed a $20M Series B in February 2026.
The record
- Vertical
- Devices & Robotics
- Sub-segment
- Implantable drug delivery
- Product type
- Device
- Stage
- Series B
- Headquarters
- Baltimore, Maryland
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $20M raised
Notable investors: NIH Blueprint MedTech.
Also in Devices & Robotics
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Biophysical Tumor Barrier: Inside TriSalus's TriNav Advance Clearance and the Fluid Mechanics of Interventional Oncology
Dr. Dereck Mush, MD, MBA
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
The Post-REMS Long-Acting Psychiatric Revolution: How Subcutaneous Copolymer Delivery Unlocks Olanzapine Outpatient Economics
Dr. Dereck Mush, MD, MBA